Login to Your Account



$50M Up Front

Portola Inks $470M Deal with Merck for Phase II Anticoagulant

By Trista Morrison


Friday, July 10, 2009
Five months after signing a $575 million deal with Novartis AG for the Phase II antiplatelet drug elinogrel, Portola Pharmaceuticals Inc. nailed down a $470 million deal with Merck & Co. Inc. for its other lead compound, the Phase II anticoagulant betrixaban. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription